Alvotech (NASDAQ:ALVO) Shares Up 6.8% – Here’s What Happened

Alvotech (NASDAQ:ALVO)’s share price rose 6.8% during trading on Thursday . The stock traded as high as $4.37 and last traded at $4.26. Approximately 796,346 shares traded hands during mid-day trading, an increase of 25% from the average session volume of 638,732 shares. The stock had previously closed at $3.99.

Key Stories Impacting Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech signed a licensing and commercialization agreement with Lotus Pharmaceutical covering proposed biosimilars AVT34, targeting Imfinzi (durvalumab), and AVT87, targeting Hemlibra (emicizumab), in the United States and selected Asian markets. The deal is valued at up to approximately $150 million and expands Alvotech’s potential commercial reach. Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical
• Positive Sentiment: The FDA accepted resubmitted applications for AVT05, a proposed Simponi biosimilar, AVT06, a proposed Eylea biosimilar, and partner Dr. Reddy’s AVT03, targeting Prolia/Xgeva. FDA decisions are expected in the fourth quarter of 2026, creating important approval and launch catalysts. Alvotech Announces Financial Results for the First Half of 2026
• Positive Sentiment: Alvotech said manufacturing returned to planned operating levels near the end of the second quarter after facility improvements constrained output. Management expects stronger product availability and commercial performance in the second half, supported by strong underlying demand in the U.S. and Europe.
• Positive Sentiment: The company projects 2026 revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million. It also strengthened liquidity with approximately $165 million from an equity offering and private placement, plus a new $75 million term loan.
• Neutral Sentiment: Alvotech’s Reykjavik facility received a “Voluntary Action Indicated” classification following an FDA inspection, a favorable compliance outcome but not a product approval.
• Negative Sentiment: First-half adjusted revenue fell 30.8% to $211.9 million, while product and service revenue dropped 48.3%. Adjusted EBITDA declined to $46.9 million, and cash decreased to $142.8 million, highlighting execution and liquidity concerns.
• Negative Sentiment: Second-quarter adjusted loss was $0.11 per share, wider than the expected $0.05 loss, although quarterly revenue of $105.77 million exceeded estimates. The equity financing also creates potential shareholder dilution.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ALVO. Evercore initiated coverage on shares of Alvotech in a research report on Friday, August 14th. They set an “outperform” rating on the stock. Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings downgraded shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Alvotech presently has a consensus rating of “Hold” and an average target price of $7.60.

Alvotech Price Performance

The firm’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $3.75. The company has a market capitalization of $1.34 billion, a PE ratio of -7.26 and a beta of 0.18.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). Alvotech had a negative net margin of 36.31% and a negative return on equity of 11.92%. The company had revenue of $105.77 million for the quarter, compared to analysts’ expectations of $103.00 million. On average, equities research analysts anticipate that Alvotech will post 0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ALVO. Geode Capital Management LLC boosted its position in Alvotech by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock worth $2,100,000 after purchasing an additional 1,574 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Alvotech by 24.0% during the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock worth $71,000 after purchasing an additional 2,675 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock valued at $78,000 after purchasing an additional 3,110 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Alvotech by 30.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,455 shares of the company’s stock valued at $200,000 after purchasing an additional 5,697 shares in the last quarter. Finally, Amundi lifted its stake in shares of Alvotech by 71.0% in the 3rd quarter. Amundi now owns 19,416 shares of the company’s stock valued at $167,000 after purchasing an additional 8,059 shares during the period.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).